Adicet Bio Inc是一家临床阶段生物技术公司。该公司致力于发现和开发异基因γ-δT细胞治疗癌症。它正在开发一条现成的γ-δT细胞管道,用嵌合抗原受体(CAR)和T细胞受体样抗体(TCRL)进行工程设计,以增强选择性肿瘤靶向性,促进先天性和适应性抗肿瘤免疫反应,并提高患者持久活动的持续性。其主要候选产品ADI-001是一种表达CAR靶向CD20的异基因γ-δT细胞疗法,目前正在进行非霍奇金淋巴瘤治疗的I期研究。其管道还包括ADI-002,一种表达GPC3靶向CAR和细胞内在可溶性形式的白细胞介素-15的异基因γδCAR-T细胞疗法,用于治疗实体瘤。此外,该公司还从事血液系统恶性肿瘤和实体瘤候选产品的发现和临床前阶段活动。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Chen Schor | CEO, President & Director | 2020 | 54 |
| Jeffrey Allan Chodakewitz | Independent Director | 2020 | 71 |
| Steve Dubin | Independent Director | 2020 | 72 |
| Andrew Sinclair | Lead Independent Director | 2025 | 54 |
| Lloyd Klickstein | Independent Director | 2024 | 69 |
| Michael J. Grissinger | Director | 2025 | 73 |
| Marco L. Davila | Member of Scientific Advisory Board | 2021 | - |
| Michael Kalos | Member of Scientific Advisory Board | 2021 | - |
| Saul Priceman | Member of Scientific Advisory Board | 2021 | - |
| Constantine Mitsiades | Member of Scientific Advisory Board | 2021 | - |
| Alice Bertaina | Member of Scientific Advisory Board | 2021 | - |
| Katie Peng | Independent Director | 2023 | 54 |